Evidence map›Paper›PMID 36420584›Full record

ArticleJournal of medical virology2023

Immune repertoire sequencing reveals an abnormal adaptive immune system in COVID-19 survivors.

Chen Jia, Zhiguo Zhou, Wenjing Pan, Pan Zhang, Ming Yang, Mingming Zhao, Bo Li, Ping Liu, Qianqian Zhang, Xianglong Kong and 10 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of medical virology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.8field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 6 institutions in 2 countries.

Chen JiaHunan Key Laboratory of Medical Epigenomics, Department of Dermatology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.ORCID 0000-0003-4073-5450
Zhiguo ZhouThe First Hospital of Changsha, Changsha, Hunan Province, China.
Wenjing PanNanjing ARP Biotechnology Co., Ltd., Nanjing, Jiangsu, China.
Pan ZhangHunan Provincial Key Laboratory of Clinical Epidemiology, Xiangya School of Public Health, Central South University, Changsha, China.
Ming YangHunan Key Laboratory of Medical Epigenomics, Department of Dermatology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
Mingming ZhaoHunan Key Laboratory of Medical Epigenomics, Department of Dermatology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
Bo LiThe First Hospital of Changsha, Changsha, Hunan Province, China.
Ping LiuThe First Hospital of Changsha, Changsha, Hunan Province, China.
Qianqian ZhangThe First Hospital of Changsha, Changsha, Hunan Province, China.
Xianglong KongThe First Hospital of Changsha, Changsha, Hunan Province, China.
Keyu LiThe First Hospital of Changsha, Changsha, Hunan Province, China.
Tingting YueHunan Provincial Key Laboratory of Clinical Epidemiology, Xiangya School of Public Health, Central South University, Changsha, China.
Ting CaiHunan Provincial Key Laboratory of Clinical Epidemiology, Xiangya School of Public Health, Central South University, Changsha, China.
Zijun WangInstitute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Erik De ClercqDepartment of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, KU Leuven, Leuven, Belgium.
Song LiHunan Key Laboratory of Biomedical Nanomaterials and Devices, Hunan University of Technology, Zhuzhou, Hunan, China.
Guangdi LiHunan Provincial Key Laboratory of Clinical Epidemiology, Xiangya School of Public Health, Central South University, Changsha, China.ORCID 0000-0001-8852-034X
Jiyang LiuThe First Hospital of Changsha, Changsha, Hunan Province, China.
Haijing WuHunan Key Laboratory of Medical Epigenomics, Department of Dermatology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
Qianjin LuHunan Key Laboratory of Medical Epigenomics, Department of Dermatology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
Central South University · CNThe First Hospital of Changsha · CNChinese Academy of Medical Sciences & Peking Union Medical College · CNHunan University of Technology · CNNanjing Institute of Railway Technology · CNRega Institute for Medical Research · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Accumulating evidence suggests that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) impairs the adaptive immune system during acute infection. Still, it remains largely unclear whether the frequency and functions of T and B cells return to normal after the recovery of Coronavirus Disease 2019 (COVID-19). Here, we analyzed immune repertoires and SARS-CoV-2-specific neutralization antibodies in a prospective cohort of 40 COVID-19 survivors with a 6-month follow-up after hospital discharge. Immune repertoire sequencing revealed abnormal T- and B-cell expression and function with large T cell receptor/B cell receptor clones, decreased diversity, abnormal class-switch recombination, and somatic hypermutation. A decreased number of B cells but an increased proportion of CD19

Indexed as

COVID-19Antibodies, ViralB-LymphocytesHumansProspective StudiesSARS-CoV-2SurvivorsAntibodies, ViralCOVID-19immune repertoireSARS-CoV-2

Identifiers

PMID36420584
PMCPMC10107439
OpenAlexW4309862174

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.